Understanding the Disease Progression of Acute Myeloid Leukemia in Murine Models and Identifying Therapeutic Targets for Leukemic Stem Cells

Session Number

BIO 15

Advisor(s)

Francis Suh

Dr. Hao Wang

Dr. Elizabeth Eklund, Northwestern University, Feinberg School of Medicine, Department of Hematology/Oncology

Discipline

Biology

Start Date

17-4-2024 10:25 AM

End Date

17-4-2024 10:40 AM

Abstract

To learn more about the roles of Hox A9/A10 in leukemia development, we use an in-vivo model for myeloid differentiation. Mixed lineage leukemia 1 (MLL1) is a gene rearrangement of Acute Myeloid Leukemia (AML). Ubiquitination, the addition of ubiquitin to proteins, also modifies AML

Patients with MLL-1 rearranged variation of AML do not survive for more than six months with standard cancer treatments (surgery, chemotherapy, etc.). We look for the effects of increased activity of the MLL1 gene for drug resistance in leukemia and hope to find new treatments. In addition, bone marrow transplants are performed in murine models to study how different treatments affect leukemia cells and determine how leukemia is caused by Hox proteins. Integrated stress responses (ISRs) are homeostatic responses that help cells adapt to their environment and maintain themselves, working against cancer treatments. Specific doses and combinations of drugs are tested on these murine models, and their effects are measured to determine the future effects of exposing humans to these same drug combinations and dosages.

Share

COinS
 
Apr 17th, 10:25 AM Apr 17th, 10:40 AM

Understanding the Disease Progression of Acute Myeloid Leukemia in Murine Models and Identifying Therapeutic Targets for Leukemic Stem Cells

To learn more about the roles of Hox A9/A10 in leukemia development, we use an in-vivo model for myeloid differentiation. Mixed lineage leukemia 1 (MLL1) is a gene rearrangement of Acute Myeloid Leukemia (AML). Ubiquitination, the addition of ubiquitin to proteins, also modifies AML

Patients with MLL-1 rearranged variation of AML do not survive for more than six months with standard cancer treatments (surgery, chemotherapy, etc.). We look for the effects of increased activity of the MLL1 gene for drug resistance in leukemia and hope to find new treatments. In addition, bone marrow transplants are performed in murine models to study how different treatments affect leukemia cells and determine how leukemia is caused by Hox proteins. Integrated stress responses (ISRs) are homeostatic responses that help cells adapt to their environment and maintain themselves, working against cancer treatments. Specific doses and combinations of drugs are tested on these murine models, and their effects are measured to determine the future effects of exposing humans to these same drug combinations and dosages.